Articles
PD-L1 expression is a rational biomarker to predict response to PD-1/PD-L1 ICI therapy, and has been studied extensively in clinical trials. A recurring theme emerging from available clinical data is that high levels of tumor cell membrane PD-L1 expression correlate with better outcomes with PD-1/PD-L1 blockade.
Testing in Patients with Cancer Clearly, immunotherapy has come of age in multiple tumor types, as described in the main article in this publication. The question now is how to develop more personalized immunotherapy and use biomarkers to identify patients most likely to benefit from this therapy.
In the main article of this publication, the current state of programmed-cell death-1 and programmed-cell death ligand-1 (PD-L1) testing, evasion by tumors of the immune system, and the study and use of immune checkpoint inhibitors across multiple tumor types are expertly summarized.
By Wayne Kuznar
In the FDA’s dynamic regulatory environment, the patient voice has been adopted and end points for clinical trials have evolved from overall survival to other efficacy measures. “Having multiple drugs is a good thing. Many are approved on nonsurvival end points, and they have transformed the diseases,” said Richard Pazdur, MD.
By Wayne Kuznar
The NCCN’s first guideline for side effects from immunotherapy recognizes a new spectrum of events in patients who are receiving immune checkpoint inhibitor therapy.
“The wide range of potential immune-related adverse events requires multidisciplinary, collaborative management by providers across the clinical spectrum,” according to Michael A. Postow, MD, and colleagues.
Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients.
Dr Andrey Antov sees much potential for navigators when it comes to applying genetic and genomic testing to cancer care.
Dr Andrey Antov expands on how the healthcare team can work together to provide the best possible care for their patient.
Dr Andrey Antov recognizes how important the role of the navigator is in dealing with genetic and genomic testing, as the navigator often needs to help the patient gain access to the appropriate therapy, work with different stakeholders, monitor data, and more.